About Us

START Madrid is dedicated to the conduct of Phase I Clinical Trials of novel anticancer agents.


The mission of START Madrid is to accelerate the development of new anticancer drugs with the purpose of improving quality of life and survival for patients with cancer. START Madrid consists of a team of highly trained physicians and staff with extensive experience in Phase I clinical trials research.


START Madrid currently has two Phase I Oncology Units: START Madrid-CIOCC, which opened in 2008, and START Madrid-FJD, which opened in 2014. The two Madrid sites are designed to work together synergistically enabling START Madrid to provide all patients in Madrid and abroad who are eligible to participate in a Phase I study access to our innovative drugs, regardless of their health coverage system and without exception: The National Public Health System in START Madrid-FJD (at Hospital Fundación Jiménez Díaz), and the Private Health System in START Madrid-CIOCC (at Centro Intengral Oncológico Clara Campal).


START Madrid was firstly opened at CIOCC (Centro Intengral Oncológico Clara Campal) of Hospital HM Universitario Sanchinarro in  October 2008, and was the first of several planned global satellite twin partners of START San Antonio (USA).


The addition of its second site in Madrid further advances START’s mission of accelerating the development of new anticancer drugs through a dedicated, 24-hour,round-the-clock network of START Centers operating in different time zones around the world.


START Madrid shares the same Standard Operating Procedures, central budgeting, efficient and proactive IT systems, eMRs, highly specialized organization, an expert and fully dedicated staff, as it occurs in the original START Program in San Antonio.  


START Madrid is led by Emiliano Calvo, M.D., Ph.D., Director of Clinical Research. 


START Madrid Clinical  Research is organized into three main highly specialized areas that work  in a highly integrated manner to facilitate the conduct of clinical trials of only the highest quality.

  • Investigational Pharmacy, headed by Ana Díez, BCOP.
  • Nursing & PK  Departments , headed by Esther Ordoñez, RN.
  • Regulatory Affairs & Data Management Departments , headed by Beatriz Tapia, Ph.D.

This International program is the first step in our goal to keep the development of anticancer agents operating 24 hours a day. Because of the work of scientists like those at START and START Madrid, real progress is being made against cancer. Through the hard work of these physicians and the continuing advances in technology we are able to improve the tools to understand, detect, and diagnose cancer. Today, people with cancer are living longer than ever before with a better quality of life.


START A Global Company

"Our sole mission is to accelerate the development of new therapies for the treatment and eventual cure of cancer by taking the skills and expertise that has been created here and expanding it to the rest of the world.”  

--Dr. Anthony Tolcher